Eurobact II
Research type
Research Study
Full title
Epidemiology and determinants of outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care. (Eurobact II)
IRAS ID
256489
Contact name
Andrew Conway Morris
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
Duration of Study in the UK
0 years, 2 months, 30 days
Research summary
Sepsis is recognised as one of the leading causes of mortality and has become a global healthcare priority. It is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. In a large multinational study Infections were thought to be present in 51% of ICU patients, of which 30% were culture negative.
Blood stream infection (BSI) is defined as the presence of a pathogen in the blood stream of a patient. As such, and once contaminants are excluded, BSI is the only cause of sepsis where the presence of an infection and the pathogen are known with certainty. This makes BSI the perfect model of infection to study the effects of the micro-organism on the patient, and the effects of the antibiotics and other treatments on survival.
The Eurobact 1 study collected multinational data on HA-BSI in 2010-11 as part of a large multicentric collaboration coordinated by the infection section of the ESICM. It has been topical in describing the relationship between antimicrobial resistance (AMR) and increased delays in effective drug therapy and how resistance is independently associated with mortality. Recent changes in the overall management of patients with sepsis and shock and a reported change in prognosis makes it urgent to obtain current data on HA-BSI in the critically ill.
Eurobact 2 was developed by the infection section of the ESICM to specifically answer those questions and recommendations. By targeting HA-BSI in a large multinational study we will obtain granular data and investigate how management and outcomes of may have changed while there has been a worldwide increase in AMR.
Eurobact II will obtain data from routinely collected clinical data concerning patients who develop hospital-acquired blood-stream infections whilst in the Intensive Care Unit. It is a prospective, observational cohort study.REC name
Yorkshire & The Humber - South Yorkshire Research Ethics Committee
REC reference
19/YH/0236
Date of REC Opinion
11 Jul 2019
REC opinion
Favourable Opinion